Argenx banks on key prefilled syringe approval for Vyvgart to help drive profitability in 2025: exec
Heading into 2025, the chief item on argenx’s agenda is the FDA’s April 10 target action date to decide on the approval of a prefilled syringe version of Vyvgart—also known as efgartigimod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback